| Identification | Back Directory | [Name]
1H-Benzimidazole-6-carboxylic acid, 2-[4-(4-nitrophenyl)-2-thiazolyl]hydrazide | [CAS]
946857-84-7 | [Synonyms]
1H-Benzimidazole-6-carboxylic acid, 2-[4-(4-nitrophenyl)-2-thiazolyl]hydrazide | [Molecular Formula]
C17H12N6O3S | [MOL File]
946857-84-7.mol | [Molecular Weight]
380.38 |
| Chemical Properties | Back Directory | [density ]
1.567±0.06 g/cm3(Predicted) | [storage temp. ]
4°C, protect from light | [form ]
Solid | [pka]
9.16±0.43(Predicted) | [color ]
Yellow to orange |
| Hazard Information | Back Directory | [Biological Activity]
BSc3094 is a Tau aggregation inhibitor. BSc3094 can be used for the research of Alzheimer’s disease (AD)[1].
BSc3094 (3 mg/kg; i.v.) direct intraventricular administration reduces sarkosyl-insoluble Tau[1].BSc3094 (0.075~1.5 mM; intraventricular administration) reduces the levels of sarkosyl-insoluble Tau in cortical extracts by ≈70%[1].BSc3094 reverses the pre-synaptic impairment in organotypic hippocampal slices from pro-aggregant mice, by reversing the pairedpulse depression observed in non-treated pro-aggregant Tau slices after applying a paired-pulse stimulus of the Schaffer collaterals. BSc3094 reverses the increase in Tau phosphorylation levels in rTg4510 mice down to control level. BSc3094 partially reversed the memory deficits in rTg4510 mice[1]. | [storage]
4°C, protect from light | [References]
[1]. Anglada-Huguet M, et al. Inhibition of Tau aggregation with BSc3094 reduces Tau and decreases cognitive deficits in rTg4510 mice. Alzheimers Dement (N Y). 2021;7(1):e12170. Published 2021 Jun 1. |
|
|